Hansa Biopharma AB (publ), a biopharmaceutical company, engages in development and commercialization of treatments for patients with rare immunological conditions in Sweden, North America, and rest of Europe. The company offers Idefirix(imlifidase), which targets and cleaves all classes of immunoglobulin G (IgG) antibodies for the desensitization treatment of sensitized adult kidney transplant patients with a positive crossmatch test. It also develops HNSA-5487, a next generation IgG-cleaving enzyme to address acute and chronic neuro-autoimmune conditions, including myasthenia gravis. In addition, the company evaluates imlifidase in three therapy areas, including autoimmune, gene therapy, and transplantation. It has a collaboration agreement with Sarepta Therapeutics to assess imlifidase as a pre-treatment in limb-girdle muscular dystrophy (LGMD) and duchenne muscular dystrophy (DMD) and research and development collaboration agreement with Genethon to evaluate the safety and efficacy of imlifidase as pre-treatment to gene therapy in Crigler-Najjar syndrome patients with anti-AAV antibodies. Hansa Biopharma AB (publ) was formerly known as Hansa Medical AB (publ) and changed its name to Hansa Biopharma AB (publ) in December 2018. Hansa Biopharma AB (publ) was incorporated in 2007 and is headquartered in Lund, Sweden.
Frequently asked questions
What sector does Hansa Biopharma AB (HNSA) operate in?
Hansa Biopharma AB belongs to the Healthcare sector and operates in the Biotechnology industry.
What is Hansa Biopharma AB (HNSA) current stock price?
As of the latest data, Hansa Biopharma AB stock price is SEK 40.36, with a previous close of SEK 41.02. Hansa Biopharma AB lost -SEK 0.66 in the last trading session, representing a -1.61% loss.
What is Hansa Biopharma AB (HNSA) current market capitalization?
Hansa Biopharma AB market cap is approximately 4.03 billion.
What is Hansa Biopharma AB (HNSA) Earnings Per Share (EPS)?
The trailing EPS is -SEK 7.65, and the forward EPS is -SEK 5.32.
What is Hansa Biopharma AB (HNSA) EBITDA?
Hansa Biopharma AB EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) is -189.72 million.
Does Hansa Biopharma AB (HNSA) pay dividends?
No. Hansa Biopharma AB does not pay a dividend.
How did Hansa Biopharma AB (HNSA) perform in its most recent earnings report?
In the last report (June 30, 2026), Hansa Biopharma AB posted an EPS surprise of -653.33% and a revenue surprise of -75.99%.
When is Hansa Biopharma AB (HNSA) next earnings report?
Hansa Biopharma AB is expected to release its next earnings report on September 30, 2026.
What is Hansa Biopharma AB (HNSA) beta (volatility) score?
Hansa Biopharma AB has a beta of 1.587, suggesting it is more volatile than the market.
